ansofaxine
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02055300)
Timeline
Indications
Mechanism of action
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly03005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03822065 | Phase 1 | Jan 16, 2019 | Luye Pharma |
| NCT04853407 | Phase 3 | Dec 5, 2018 | Luye Pharma, Peking University |
| NCT03733574 | Phase 1 | Jun 19, 2018 | Luye Pharma |
| NCT03357796 | Phase 1 | Nov 27, 2017 | Luye Pharma |
| NCT02988024 | Phase 1 | Dec 7, 2016 | Luye Pharma |
| NCT03785652 | Phase 1 | Oct 9, 2015 | Luye Pharma |
| NCT02271412 | Phase 1 | Oct 1, 2014 | Luye Pharma, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT02055300 | Phase 1 | Feb 1, 2014 | Luye Pharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Luye Pharma | For profit | 8 | 8 | 2 | 2014 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1